iPSC-derived CAR-NK cells for systemic sclerosis

IF 32.7 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2025-08-06 DOI:10.1038/s41584-025-01292-z

Holly Webster

引用次数: 0

Abstract

A chimeric antigen receptor (CAR)-natural killer (NK) cell therapy shows promise in a patient with severe systemic sclerosis and offers a scalable, off-the-shelf developmental approach.

查看原文本刊更多论文

ipsc衍生CAR-NK细胞治疗系统性硬化症

嵌合抗原受体(CAR)-自然杀伤（NK）细胞疗法在严重系统性硬化症患者中显示出希望，并提供了一种可扩展的、现成的发展方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.